Although laser eye surgery is the most common way to gain freedom from glasses or contact lenses, some people’s eyes aren’t suitable due to high prescriptions or thin corneas. In these cases implantable contact lens (ICL) may be a better solution for their vision problems.
Over 125,000 Visian ICL’s have been implanted worldwide with excellent results. All our ICL patients have achieved unaided vision of better than, or equal to, driving vision.
The ICL is a tiny contact lens that is placed inside the eye, not on top of the eye like normal contact lenses, to correct near or far (short or long) sightedness, with or without astigmatism. The lens is specially manufactured for your individual eye contours, so is highly customised. Our specialist can advise if ICL is the right choice for you.
For further information on ICL please contact our friendly specialist team.
Auckland Eye is pleased to be able to offer this technology and Dr Dean Corbett has been fully accredited by STAAR™ since September 2003 and has performed over 70 ICL procedures over this time with excellent results as outlined.
Ideally the first eye will be followed by the second after a period of at least 2 days, but more commonly 1-2 weeks. Alternatively a contact lens can be worn in the non-operated eye, and the second ICL can be deferred for an indefinite period. All patients not living in Auckland would be asked to remain within the Auckland metropolitan area for a minimum of 1 days post implantation of an ICL.
All ICL surgery will be performed at Auckland Eye, Remuera.
All patients will receive a local anaesthetic. General anaesthesia is an option , but not necessary, and will increase the cost of the procedure.
Surgery is performed early in the afternoon, as a postoperative check is required 4 hours later. Further follow-ups are required at 1 day, 1-2 weeks, and 1-2 months, and any additional as required. Longer term follow-up will occur at 6 months and 2 year intervals. All follow-ups for the first six months will be included in the initial fee. Subsequent visits will take place annually or as required, and will be charged as a follow-up visit. Current results suggest that patients that are stable at 3 months are unlikely to develop any significant problems.
Frequently Asked Questions
An Implantable Contact Lens (ICL) is a small implanted lens that is placed inside the eye to correct near or far (short or long) sightedness, with or without astigmatism.
There are now a number of different ways to correct focusing errors with surgery. The choice of which surgery is best depends on many factors. These include:
- level of focusing error
- suitability for laser eye surgery,
- and personal expectations from the surgery
Our surgeon will be able to advise you on which technique will best suit you. In general, those patients currently choosing ICL are those who are not suitable for laser eye surgery, or those who prefer a technique that adds an increased component of ‘reversibility’.
Whilst laser eye surgery works very well for most focusing errors, there are areas where ICL’s are preferred. For nearsightedness, the clarity of vision may start to become reduced after laser surgery above a level of -8. For other patients, even a -6 prescription may be too high because of an unacceptable risk of introducing reduced quality of vision, especially in dim lighting conditions. Levels above +4 for farsightedness may cause similar problems with laser surgery.
Occasionally, we find patients eyes are not suitable because they are structurally weaker, or more prone to eye diseases, meaning laser surgery could permanently make their vision worse.
In these cases ICL surgery may provide a solution as the procedure does not weaken the cornea (front surface of the eye).
Therefore in many cases, particularly those with a large focusing error, a patient’s clarity of vision will be better with an ICL than with laser eye surgery.
Over 125,000 Visian ICL’s have been implanted worldwide. Large scientific studies (as early as October 2001) have demonstrated ICL’s to be safe, effective and provide accuracy of results. Though no surgery is ever 100% safe, ICL implants have been given preliminary approval for use by the FDA in the United States. In the FDA trial, 523 eyes with ICL implantation were followed. 47.3% of eyes gained 20/20 (100% perfect vision) or better and 91.8% 20/40 (legal driving vision) or better.
All eyes implanted with the STAAR™ ICL at Auckland Eye have achieved unaided vision of better than or equal to driving requirements.
67% achieved 20/20 vision, and 71% are seeing better after ICL implantation than they were able to with their glasses preoperatively. No patients have lost any vision, and all have either had their second eye implanted or expressed a desire to do so.
Patients who are particularly suitable for this lens are as follows:
- Inadequate corneal thickness for a laser eye surgery
- Forme Fruste or Clinical Keratoconus
- Previous herpetic eye disease
- Near-Sightedness (Myopia) > -8D
- Far-Sightedness (Hypermetropia) >4D
- Collagen vascular disease or other contraindications for laser
Patients who are unsuitable are:
- Small eyes (inadequate anterior chamber depth (<2.8mm))
- Irregular astigmatism rendering poor BCVA
ICL Implants have a very similar recovery period to modern laser eye surgery. It is unusual, but not uncommon for patients to see quite well after 4 hours. Almost all patients are achieving a very satisfactory level of vision within the first 24 hours. Except for swimming, there are no activities that are specifically restricted during the recovery period. Recommendations regarding activities may be made depending on the vision in the other eye.
Compared to laser eye surgery the ICL procedure utilises an expensive implant manufactured to high quality Swiss standards. The ICL is not held in stock and is ordered, couriered and in some instances ‘hand-made’ to fit a specific patient’s eye, thus production costs are significant.
As opposed to laser eye surgery, the ICL implant requires a fully sterile operating theatre environment and the presence of an anaesthetist, which adds considerably to the cost of the procedure.
This is exceedingly uncommon, but a critical and potential complication with any eye surgery. Because ICL implantation is a short and relatively non-invasive operation, the best estimate of risk is very low around 1:3000.
Should an infection occur the eventual visual outcome would depend on the speed of diagnosis, delay in antibiotic administration, type of bacteria or organism involved, and host/pathogen response.
Actual outcomes post infection can range from excellent (where the infection has had no effect on the post-operative result) to blindness. Post operative monitoring is therefore critical.
In the FDA trial leading to the approval of ICL, only 0.8% of 523 eyes implanted with the ICL developed symptomatic lens opacities (cataract). Removal of these cataracts has not been associated with a significant increase in poor visual outcome.
Recent reports indicate that this complication is much rarer than previously thought. The worst scenario is that a cataract can develop and impair eyesight, which means cataract surgery would be needed to restore eyesight to an acceptable level of vision. Cataract surgery at the present time is the most successful surgical procedure in medicine and is a great backup should this unlikely outcome arise. The reason that this procedure is not undertaken rather than ICL implantation is that in highly nearsighted patients there is increased risk for retinal detachment, and in both near and far sighted candidates there is generally immediate loss of near vision without the addition of reading glasses. This risk is still a very significant factor if cataract surgery becomes necessary as a result of a cataract forming following the ICL procedure.
Residual refractive error (blurriness)
Estimates made to determine the most appropriate ICL though very accurate are not 100% accurate. In a small group of patients, around 3%, the ICL will need to be exchanged for a more suitable power. The costs involved in this further surgery will be borne by STAAR™ and Auckland Eye, however further surgery would only be offered if the risk/benefit ratio was clearly in your best interests. As with all refractive, laser, incisional or intraocular surgery, there is no guarantee that a given level of vision will be achieved. The likelihood of improving unaided vision to a level of your satisfaction is however very high.
There is a potential long-term risk of glaucoma. The ultimate result in patients with uncontrolled glaucoma is blindness. In this country, this is an extremely unlikely outcome for patients because you will be monitored long term. Any risk of glaucoma will be identified very early and treatment either in the form of drops, laser or incisional surgery will be administered in order to minimise the chance of any visual loss. The incidence of glaucoma with this implant remains exceedingly low. There were no cases reported in the FDA trial.